- Home
- PSNYW vs MREO Comparison
PSNYW vs MREO Comparison
Compare PSNYW & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- MREO
- Stock Information
- Founded
- PSNYW 2017
- MREO 2015
- Country
- PSNYW Sweden
- MREO United Kingdom
- Employees
- PSNYW N/A
- MREO N/A
- Industry
- PSNYW Auto Manufacturing
- MREO Biotechnology: Pharmaceutical Preparations
- Sector
- PSNYW Consumer Discretionary
- MREO Health Care
- Exchange
- PSNYW Nasdaq
- MREO Nasdaq
- Market Cap
- PSNYW 362.3M
- MREO 369.2M
- IPO Year
- PSNYW N/A
- MREO N/A
- Fundamental
- Price
- PSNYW $0.16
- MREO $2.41
- Analyst Decision
- PSNYW
- MREO Strong Buy
- Analyst Count
- PSNYW 0
- MREO 7
- Target Price
- PSNYW N/A
- MREO $7.71
- AVG Volume (30 Days)
- PSNYW 42.8K
- MREO 1.5M
- Earning Date
- PSNYW 03-06-2025
- MREO 05-19-2025
- Dividend Yield
- PSNYW N/A
- MREO N/A
- EPS Growth
- PSNYW N/A
- MREO N/A
- EPS
- PSNYW N/A
- MREO N/A
- Revenue
- PSNYW $2,046,740,000.00
- MREO N/A
- Revenue This Year
- PSNYW N/A
- MREO N/A
- Revenue Next Year
- PSNYW $79.49
- MREO $56.11
- P/E Ratio
- PSNYW N/A
- MREO N/A
- Revenue Growth
- PSNYW N/A
- MREO N/A
- 52 Week Low
- PSNYW $0.09
- MREO $1.58
- 52 Week High
- PSNYW $0.61
- MREO $5.02
- Technical
- Relative Strength Index (RSI)
- PSNYW 46.26
- MREO 50.36
- Support Level
- PSNYW $0.16
- MREO $2.28
- Resistance Level
- PSNYW $0.17
- MREO $2.75
- Average True Range (ATR)
- PSNYW 0.01
- MREO 0.16
- MACD
- PSNYW 0.00
- MREO -0.00
- Stochastic Oscillator
- PSNYW 25.10
- MREO 27.66
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market-leading standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from USA.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. The Company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).